Pharmaceuticals, Biotechnology and Life Sciences
BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of…
Results show exciting promise for reducing dependence on medications and alleviation of the massive cost burden for people living with…
Company secures two oral and four poster presentations Presentations include new data highlighting the antiviral effect and immune system engagement…
SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be…
—RVT-802, a one-time therapy, leverages Enzyvant’s T cell generation platform designed to treat profound immunodeficiencies— —Left untreated, congenital athymia is…
—RVT-802, a one-time therapy, leverages Enzyvant’s T cell generation platform designed to treat profound immunodeficiencies— —Left untreated, congenital athymia is…
Wednesday programming will feature timely discussions on diversity, inclusion and R&D investment PHILADELPHIA–(BUSINESS WIRE)–The 2019 BIO International Convention, the premier…
Wednesday programming will feature timely discussions on diversity, inclusion and R&D investment PHILADELPHIA–(BUSINESS WIRE)–The 2019 BIO International Convention, the premier…
LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label…
LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of an open label…